Sponsored by
Ruxolitinib is a JAK Inhibitors that is FDA approved for the treatment of blood and bone marrow cancers. They are testing it in addition to radiation and Temozolomide for Glioblastoma and early results look good, and the side effects were not too bad. If this proves to be useful, it can be used off label immediately.